France’s Sanofi-Aventis has agreed to raise its bid for Genzyme (GENZ) to the low $70’s per share range, plus a milestone payment based on the performance of an experimental drug, a source familiar with the situation told Reuters on Tuesday.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!
Leave a Reply